PESAB06 | Cryptococcus qPCR assays: the future for routine mycology labs and clinical trials dealing with HIV-associated cryptococcosis | Poster exhibition | Diagnostics of co-infections and co-morbidities |
PESAB07 | Antenatal systemic inflammation and mortality of children born to mothers with HIV in rural Zimbabwe | Poster exhibition | Biomarkers for the prediction of morbidity and mortality |
PESAB08 | Viral suppression among adults with HIV receiving dolutegravir-based antiretroviral therapy and 3HP in Kampala, Uganda | Poster exhibition | Tuberculosis: Prevention, diagnosis, treatment |
PESAB09 | Pharmacokinetic and 48 week efficacy of once-daily vs twice-daily dolutegravir among patients with human immunodeficiency virus/tuberculosis coinfection receiving rifampicin based tuberculosis therapy: a randomized control trial | Poster exhibition | Tuberculosis: Prevention, diagnosis, treatment |
PESAB10 | Sitafloxacin therapy for mycoplasma genitalium in men who have sex with men | Poster exhibition | STIs (including HPV) |
PESAB11 | The acceptability of the AMBITION treatment regimen for HIV-associated cryptococcal meningitis: findings from a qualitative study of patients and providers in Botswana and Uganda | Poster exhibition | Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections |
PESAB12 | Efficacy of cefixime for the treatment of Neisseria gonorrhoeae infection at three anatomic sites: a systematic review and meta-analysis | Poster exhibition | STIs (including HPV) |
PESAB13 | Cumulative HIV-1 viremia is associated with multimorbidity among U.S. women with HIV | Poster exhibition | Cardiovascular disease |
PESAC01 | Prevalence and individual and community-level risk factors of advanced HIV disease among people living with HIV from nine African countries | Poster exhibition | Epidemiology of HIV in the general population |
PESAC02 | High transmitted drug resistance in Brazil: unprecedented levels of INSTI resistance | Poster exhibition | Epidemiology of HIV in the general population |